 |
US delays decision on Takeda diabetes drugJapan's Takeda Pharmaceutical Company said US regulators had extended their review of its diabetes drug alogliptin, requesting additional data on what the company hopes will be the successor to its top-selling Actos drug. &n More… |
Tuesday 24 December 2024
